📣 The “Women in Modelling at @LSHTM” initiative has been awarded US$100,000 by @gatesfoundation!
🖥️ The project, led by @kiesha_prem & @yangliubeijing, will support women's career development in @cmmid_lshtm & further afield.
🔗 https://t.co/MpXOf1xuGL
My research (with @_nickdavies@cmmid_lshtm@markjit & John Edmunds) is published in @NatureComms 🥳
This is the culmination of many months of work (my funding from @Epipose)🍾🎉
https://t.co/qt4rDHGgKe
Until I write a book on this (publishers/agents hmu😝), here is a 🦣🧵
🔥Fresh preprint hot off the press!!🦠
Our study looks at the demographics and trends of COVID-19 cases, over the past few months when testing policies changed considerably in England...
1/🧵👇
https://t.co/N5SAWgVwbl
@EliseMTessier@SophieGraceNash@kallmemeg@UKHSA
Our systematic review on P. knowlesi (Pk) transmission has been published in @MalariaJournal! Authored along with @ecolokey, @ChrisDrakeley, Dr Kim Fornace, Dr Kim Lindblade and Dr Indra Vythilingham
https://t.co/VPc1KBSLl6
A short summary of the paper: 🧵
Issue 4 of the Keppel Health Review is now LIVE. Check out our cover and, contents, and the letter from our Editors-in-Chief here!
To read more, head to https://t.co/M1OXqJy8M8
#PublicHealth#magazine#health#GlobalHealth
With new analyses showing lower severity for Omicron cases, what will this mean for our projections? Well obviously this will tend to bring the numbers lower, which is great — but I want to clear up a few misconceptions.
The question of who to prioritise to receive the #CovidVaccine is a complex issue. We conducted a systematic review of economic models that assess the key groups to target and reported findings for when that prioritization can change.
https://t.co/fP6q2Nqd66
I wrote for The @Guardian on how our perception of the pandemic is shaped in part by how likely we are to know someone who has died from Covid, and how this grief is unevenly distributed:
https://t.co/jr9LGvNsYP
Late last week, it was announced that a new variant of SARS-CoV-2 (VOC 202012/01) was detected and appeared to be spreading rapidly in the south east of England. We analysed the transmissibility and severity of this new variant. [https://t.co/rYBx712GN3] NOT PEER REVIEWED 1/9
We're excited to launch a new resource today- a 'Vaccine FAQs' section of our website! We provide accessible expert answers to questions about vaccines & vaccine research, including short animations. We'll be adding to this over time. Please share!
👇👇👇
https://t.co/bjacTIJOVU
Opportunity for 3️⃣ new @LSHTM MSc students to become @LSHTM_AMR Liaison Officers ⬇️
A fantastic role I've shared with @toniakinola@ciaravmccarthy for the last year!
Deadline: 19 October 2020 ⏰
Surveys using antibody tests suggest that fewer people may have already been infected with SARS-CoV-2 than was previously thought. But the presence or absence of antibodies is far from the full story. Here’s why: https://t.co/CGUUyZ92o7
An EXCELLENT thread by Dr. Krammer that breaks down some really complex immunology really clearly and sheds some light on the whole "decaying antibodies" discussion that's currently going around.
"For every one excess #COVID19 death attributable to SARS-CoV-2 infections acquired during routine vaccination clinic visits, 84 deaths in children could be prevented" through routine immunization. Key findings from @LancetGH's benefit–risk analysis: https://t.co/vsdGqds4SX